Ipragliflozin, a SGLT2 Inhibitor, Reduced Body Weight and Fat Mass but Not Muscle Mass in Japanese Type 2 Diabetic Patients Treated with Insulin—A Randomized Clinical Trial

Objective: Weight gain is a common problem in the insulin treatment. SGLT2 inhibitors are expected to reduce body weight (BW) due to negative energy balance. Previous reports suggested that BW reduction is achieved mainly by loss of body fat, and ∼20% of reduction is by lean mass. However, the effic...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Diabetes (New York, N.Y.) N.Y.), 2018-07, Vol.67 (Supplement_1)
Hauptverfasser:	MORINO, KATSUTARO, INOUE, HIDEKA, FUSE, KEIKO, TANAKA, SACHIKO, KONDO, KEIKO, ARIMA, HISATOMI, MIURA, KATSUYUKI, SATO, DAISUKE, OHASHI, NATSUKO, IDA, SHOGO, MIYAZAWA, ITSUKO, SEKINE, OSAMU, UGI, SATOSHI, MAEGAWA, HIROSHI
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!